FAQ: Cybin Inc.'s EMBRACE Phase 3 MDD Study Receives EU Approval
Summary
Cybin Inc. has received European approval to initiate its EMBRACE Phase 3 study for CYB003, a deuterated psilocin analog, in Ireland, Poland, and Greece, targeting Major Depressive Disorder (MDD) with the aim of providing long-lasting treatment options.
What is the EMBRACE Phase 3 study about?
The EMBRACE Phase 3 study is part of Cybin’s PARADIGM program, evaluating CYB003, a proprietary deuterated psilocin analog, for the treatment of Major Depressive Disorder (MDD) in participants with inadequately controlled symptoms.
Why is the EMBRACE Phase 3 study significant?
This study is significant because CYB003 has been granted Breakthrough Therapy Designation by the FDA for MDD, indicating its potential to offer substantial improvement over existing therapies for a serious condition.
How will the EMBRACE Phase 3 study be conducted?
The study will enroll 330 participants across multiple international sites in Ireland, Poland, and Greece, assessing two CYB003 dose levels against placebo.
Who is conducting the EMBRACE Phase 3 study?
Cybin Inc., a clinical-stage neuropsychiatry company, is conducting the study as part of its commitment to developing innovative treatments for mental health conditions.
Where is the EMBRACE Phase 3 study taking place?
The study is set to launch in Ireland, Poland, and Greece, as part of Cybin’s international research efforts.
What is CYB003?
CYB003 is Cybin’s proprietary deuterated psilocin analog, currently in Phase 3 studies for the adjunctive treatment of Major Depressive Disorder, and has received Breakthrough Therapy Designation by the FDA.
How can I learn more about Cybin Inc. and its research?
For more information about Cybin Inc. and its research, visit www.cybin.com or follow the company on social media platforms like X, LinkedIn, YouTube, and Instagram.
What other treatments is Cybin developing?
Besides CYB003, Cybin is developing CYB004, a deuterated N, N-dimethyltryptamine molecule for generalized anxiety disorder, and has a pipeline of investigational, 5-HT-receptor focused compounds.
Where can I find the latest news about Cybin Inc.?
The latest news and updates about Cybin Inc. (CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 140125